JP4235037B2 - Evaluation method of skin aging degree - Google Patents
Evaluation method of skin aging degree Download PDFInfo
- Publication number
- JP4235037B2 JP4235037B2 JP2003150972A JP2003150972A JP4235037B2 JP 4235037 B2 JP4235037 B2 JP 4235037B2 JP 2003150972 A JP2003150972 A JP 2003150972A JP 2003150972 A JP2003150972 A JP 2003150972A JP 4235037 B2 JP4235037 B2 JP 4235037B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- age
- cells
- fibroblasts
- aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、皮膚の生物的な加齢変化に基づき皮膚老化度を評価する方法及び評価キットに関する。
【0002】
【従来の技術及び発明が解決しようとする課題】
皮膚の加齢変化は、しわ、たるみ等の見た目や、ハリ、弾力等の触れた場合の感触等により認知される。そのため、見た目の皮膚老化度、いわゆる肌年齢の推定は外見からの判断により比較的容易に行えるし、また、皮膚表面に接触することを前提とする機器測定を利用すればより数値的な客観的なデータから肌年齢の推定が可能である。実際、肌年齢を判定する方法としては、しわ及びたるみの外的容貌の程度により実年齢を推定する方法(例えば、特許文献1、特許文献2参照)、皮膚に振動体を接触させた時の振動変化で肌特性、肌年齢を判定する方法(例えば、特許文献3参照)、超音波皮膚画像の真皮輝度により年齢を推定する方法(例えば、特許文献4参照)が報告されている。
【0003】
しかし、皮膚の加齢変化はこれら外見や感触以前に、まず数多くの皮膚における生物的な加齢変化、例えば細胞の老化やマトリックスの老化等に始まっていると考えられる。従って、皮膚老化度は、そのような皮膚における生物的な加齢変化を指標として評価されるのが好ましいが、斯かる評価方法はほとんど知られていない。例えば、表皮の角質細胞の平均面積を指標とする年齢推定方法(例えば、特許文献5参照)が知られているが、これは最外層の角層を見るものであり、皮膚における生物的な加齢変化を追ったものとは言いがたいものであった。
【0004】
本発明は、皮膚の生物的な加齢変化に基づき皮膚の老化度を評価する方法を提供することを目的とする。
【0005】
【特許文献1】
特開2002−330943号公報
【特許文献2】
特開2002−360544号公報
【特許文献3】
特開2001−212087号公報
【特許文献4】
特開2000−83954号公報
【特許文献5】
特開平11−299792号公報
【0006】
【課題を解決するための手段】
本発明者は、非筋細胞の発生する力と加齢との関係について検討したところ、意外にも皮膚線維芽細胞の発生する力が加齢により低下することを見出し、皮膚線維芽細胞に刺激物質を添加した場合に当該細胞に発生する力の変化を測定することにより、皮膚老化度の評価が可能であることを見出した。
【0007】
すなわち本発明は、被験者由来の皮膚線維芽細胞を包埋したコラーゲンゲルに刺激物質を添加し、当該細胞に発生する力の変化を測定することを特徴とする当該被験者の皮膚老化度の評価方法を提供するものである。
【0008】
また本発明は、皮膚線維芽細胞を包埋したコラーゲンゲル、刺激物質及び細胞発生張力測定装置を備えてなる皮膚老化度の評価キットを提供するものである。
【0009】
【発明の実施の形態】
本発明評価方法においては、被験者から採取した皮膚線維芽細胞がサンプルとして用いられる。皮膚線維芽細胞は、パンチバイオプシー等により、採取することができる。採取部位は、顔面部、上腕内側部、上腕外側部、大腿内側部、大腿外側部、腹部、背部の皮膚等が挙げられ、また、評価結果の利用の方法にも依存することもあるが、非露光部でありかつ採取時の傷の目立たない腹部、上腕内側部、大腿内側部などが好ましい。
【0010】
採取された皮膚線維芽細胞は、コラーゲンゲル中に包埋され、細胞が発生する力の測定に供される。線維芽細胞のコラーゲンゲルへの包埋は公知の方法(Kolodney MS, Wysolmerski RB, Isometric contraction by fibroblasts and endothelial cells in tissue culture: a quantitative study. J Cell Biol., 117, 73-82(1992)、或いは Kolodney MS, Elson EL, Correlation of myosin light chain phosphorylation with isometric contraction of fobroblasts. J Biol Chem, 268, 23850-55(1993))により行えばよいが、例えば、以下のよう調製することができる。
【0011】
採取された皮膚線維芽細胞を、例えば5%牛胎児血清(FBS)含有ダルベッコ改変イーグル培地(DMEM)で培養し、培養線維芽細胞を定法により単離して得る。得られた細胞を300−400万cells/mLになるようにFBS含有DMEMを加え再度けん濁させる。一方、コラーゲンゲル調製溶液は、コラーゲン溶液(新田ゼラチン、typeI−A)を用いて、定法により作製する。このコラーゲンゲル調製溶液に先に調製した細胞けん濁溶液を最終濃度で細胞密度が3×105 cells/mLから5×105 cells/mLとなるよう加え、線維芽細胞包埋コラーゲンゲル調製溶液を作製することができる。
【0012】
他方、コラーゲンゲルを作製するための容器は、シリコンラバー、シリコンチューブ、布テープ、及び培養ディッシュなどを用いて作製した。シリコンラバーで作成された溝に上記の線維芽細胞包埋コラーゲンゲル調製溶液を流し込み、37℃でインキュベートしゲル化させ、24時間後さらに無血清培地中で1日から2日インキュベートして、線維芽細胞包埋コラーゲンゲルを調製することができる。
【0013】
ここで用いられるコラーゲンとしては、動物由来のコラーゲンであればよいが、特にヒト、マウス、ラット、ウサギ、モルモット、ウシ等のほ乳類由来のコラーゲンが好ましい。これらのコラーゲンは組織より公知の方法により採取して用いてもよく、又は市販品(例えば新田ゼラチン社製、typeI-A)を購入して用いてもよい。
【0014】
コラーゲンゲルに包埋された皮膚線維芽細胞に発生する力とは、アクチンーミオシンが重合して筋原線維ともいえるストレスファイバーが細胞内に形成され、それが収縮する際に発生する力であり、その測定は公知の方法(Kolodney MS, Wysolmerski RB,.J Cell Biol.,117, 73-82(1992)、Kolodney MS, Elson EL, J Biol Chem, 268, 23850-23855(1993))に従って行うことができる。
【0015】
例えば、上記で調製された線維芽細胞包埋コラーゲンゲルを、ビーカー中で37℃程度に保温した無血清培地中に片側を固定し、もう一方をアイソトニックトランスデュ−サー(例えばIsotonic Transducer、8gf、T-7-8-240、ORIENTEC, JAPAN、またはPAT-08、Physio Tech.JAPAN など)に吊るし、50−300mgに相当する負荷をかけた後、30分〜1時間程度安定化させ、その後、無血清DMEM培地で最終濃度の50倍程度の濃度に調製した刺激物質を1mL程度添加し、発生する力の変化をアイソトニックトランスデュ−サーで計測し、増幅(例えば、Physio Tech., Signal Conditioner MAC-2)後、記録(例えば、MP100A-CE、AcqKnowledge 3.5、ともに Biopack system Inc. Santabarbara)することによって行うことができる。
【0016】
刺激物質としては、線維芽細胞のアクチンーミオシン系を刺激して力(張力)を発生させる物質であればいずれのものでもよく、例えばトロンビン(Thrombin)、リソホスファチジン酸(LPA:Lysophosphatidic acid)等、が代表例として挙げられるが、牛胎児血清(FBS)、モノパルミトイルホスファチジン酸(MLPA:Monopalmitoyl phosphatidic acid)、リソホスファチジルコリンパルミトイル(LPCP:Lysophosphatidyl choline palmitoyl)、エンドセリン(ET−1: Endothelin-1)、血小板由来成長因子(PDGF:Platelet-derived growth factor)等を用いることもできる。
【0017】
ヒト腹部由来の皮膚線維芽細胞(継代数2−3)を用い、継代培養して継代数5−7の細胞と、継代数16−19(in vitro 老化線維芽細胞)を調製し、それぞれコラーゲンゲルに包埋して、トロンビン及びLPAで刺激した場合の当該線維芽細胞の発生する力を測定したところ、老化線維芽細胞ではそれぞれ4.8+/−3.3dyne、2.5+/−3.1dyne(平均値+/−SD)であり、若い線維芽細胞(それぞれ32.3+/−25.3dyne、11.3+/−6.8dyne)と比較して細胞の発生する力が有意に低下していた(実施例1)。また、62−79歳の老齢者由来の線維芽細胞と1−4歳乳幼児由来の線維芽細胞について、トロンビン刺激した場合の細胞発生する力を測定したところ、老齢者由来の細胞は13.3+/−9.0dyneであり、乳幼児由来の細胞(24.5+/−2.0dyne)と比較して有意に低下していた(実施例2)。すなわち、皮膚線維芽細胞の細胞の発生する力は、加齢と共に低下している。
従って、被験者から採取した皮膚線維芽細胞について、当該細胞の発生する力を測定することにより、被験者の細胞の老化度、皮膚の老化度を評価することができる。
【0018】
本発明の皮膚老化度の評価キットは、上記した被験者の皮膚老化度の評価方法を実施するためのキットであり、上述した皮膚線維芽細胞を包埋したコラーゲンゲル、刺激物質及び細胞発生張力測定装置(例えば、アイソトニックトランスデュ−サー等)を備えてなるものである。
【0019】
本発明の評価方法及び評価キットは、例えば手術における創傷治癒速度の推定における手術方針や、再生医療における移植皮膚の作製、選択の方針、また肌年齢に応じた化粧料の選択方法の指針等に利用し得るものである。
また、各年齢層における皮膚線維芽細胞の発生する力の値をバックグラウンドデータとして用意し、これと被験者から得られたデータを比較することにより、被験者の肌年齢の推定等が可能となる。
【0020】
【実施例】
実施例1 In vitro老化による線維芽細胞発生張力の低下
(1)細胞
ヒト皮膚線維芽細胞(age; 62, sex; male、腹部由来、継代数2−3、PDL(Population doubling time)=6−8程度)をCELL SYSTEMS社-大日本製薬より購入し、購入時の継代数を3として、5%FBS含有DMEMでコンフルエント到達時にスプリット比1:4で継代培養した。継代数5−7を若年層(Young)、継代数16−19にin vitro 老化させた老年層(Old)として比較した。
【0021】
(2)細胞発生する力の測定
コラーゲンゲル培養系で力の測定法はKolodenyらの方法に従って行った(Kolodney MS, Wysolmerski RB, Isometric contraction by fibroblasts and endothelial cells in tissue culture: a quantitative study. J Cell Biol.,117, 73-82(1992)、Kolodney MS, Elson EL, Correlation of myosin light chain phosphorylation with isometric contraction of fibroblasts. J Biol Chem, 268, 23850-23855(1993))。簡単には、線維芽細胞包埋コラーゲンゲル(1.5×106cells, 1.5mg/mL collagen,新田ゼラチンTypeI-A)を37℃に保温した無血清培地中に固定し、安定化させた後、無血清DMEMで最終濃度の50倍程度の濃度に調整した物質を1mL添加(最終濃度:トロンビン=0.2 U/mL、LPA(リソフォスファチジン酸)=10μM)し、発生する力の変化はIsotonic Transducer(8gf、T-7-8-240、ORIENTEC、JAPAN)で計測し、増幅(Physio Tech., Signal Conditioner MAC-2)後、記録(MP100A-CE、AcqKnowledge 3.5、ともにBiopack system Inc. Santabarbara)で記録した。
【0022】
図1に示したごとく、in vitro老化させた老化線維芽細胞では若い線維芽細胞と比較し、トロンビン、LPAの刺激により細胞の発生する力が有意に低下することが確認された。細胞数は同一であることから加齢により個々の細胞の発生する力が低下したと考えられる。
【0023】
実施例2 In vivo老化による線維芽細胞発生張力の低下
(1)細胞
In vivo 老化細胞細は、 DF014(age; 62, sex; male), DF151 (age; 79, sex; male), DF181 (age; 64, sex; unknown), DF146 (age; 67,sex; male), DF149 (age; 75, sex; male),以上62-79歳の老齢者由来の細胞(OLD,n=5)、及びDF374 (age; 1, sex; male), DF628 (age; 4, sex; male), DF775 (age; 3, sex; male), (age; 1, sex; male),DF287 (age; 1, sex; female), DF486(age; 2, sex; male),以上1-4歳乳幼児由来の細胞(YNG、n=5)を用いた。
【0024】
(2)細胞の発生する力の測定
実施例1と同じ方法にて行った。無血清DMEMで最終濃度の50倍程度の濃度に調整したトロンビン溶液を1mL添加(最終濃度0.2 U/mL)し、発生する力の変化をみた。
【0025】
図2に示したごとく、老齢者由来の細胞は4歳乳幼児由来の細胞と比較して、トロンビン刺激により細胞の発生する力が有意に低下することが確認された。細胞数は同一であることから加齢により個々の細胞の発生する力が低下したと考えられる。
【0026】
【発明の効果】
本発明によれば、皮膚の生物的な加齢変化に基づき被験者の皮膚老化度を評価することができる。
【図面の簡単な説明】
【図1】図1は、in vitro老化線維芽細胞のトロンビン及びLPA刺激による力の発生の低下を示した図である。
【図2】図2は、in vivo老化線維芽細胞のトロンビン刺激による力の発生の低下を示した図である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a method and an evaluation kit for evaluating the degree of skin aging based on biological aging of the skin.
[0002]
[Prior art and problems to be solved by the invention]
Skin age-related changes are recognized by the appearance of wrinkles, sagging, and the like, and when touched by elasticity, elasticity, and the like. Therefore, estimation of apparent skin aging, so-called skin age, can be done relatively easily by judgment from appearance, and more numerical objective can be achieved by using instrumental measurement that assumes contact with the skin surface. Skin age can be estimated from various data. Actually, as a method for determining the skin age, a method of estimating the actual age based on the external appearance of wrinkles and sagging (see, for example, Patent Document 1 and Patent Document 2), and a method in which a vibrating body is brought into contact with the skin. A method for determining skin characteristics and skin age based on vibration changes (for example, see Patent Document 3) and a method for estimating age based on the dermal brightness of an ultrasonic skin image (for example, see Patent Document 4) have been reported.
[0003]
However, it is considered that the aging change of the skin begins with biological aging changes in many skins such as cell aging and matrix aging before the appearance and feel. Therefore, the degree of skin aging is preferably evaluated using such biological aging changes in the skin as an index, but such an evaluation method is hardly known. For example, an age estimation method using an average area of keratinocytes in the epidermis as an index (see, for example, Patent Document 5) is known. It was hard to say that it was a change in age.
[0004]
An object of this invention is to provide the method of evaluating the aging degree of skin based on the biological aging change of skin.
[0005]
[Patent Document 1]
JP 2002-330943 A [Patent Document 2]
JP 2002-360544 A [Patent Document 3]
Japanese Patent Laid-Open No. 2001-212087 [Patent Document 4]
JP 2000-83954 A [Patent Document 5]
JP-A-11-299792 [0006]
[Means for Solving the Problems]
The present inventor examined the relationship between aging force and non-muscle cell generation, and surprisingly found that the dermal fibroblast generation force decreases with aging and stimulates dermal fibroblasts. It was found that the degree of skin aging can be evaluated by measuring the change in force generated in the cells when a substance is added.
[0007]
That is, the present invention provides a method for evaluating the degree of skin aging of a subject, comprising adding a stimulating substance to a collagen gel in which skin fibroblasts derived from the subject are embedded, and measuring a change in force generated in the cells. Is to provide.
[0008]
The present invention also provides a skin aging evaluation kit comprising a collagen gel in which skin fibroblasts are embedded, a stimulating substance, and a cell generation tension measuring device.
[0009]
DETAILED DESCRIPTION OF THE INVENTION
In the evaluation method of the present invention, skin fibroblasts collected from a subject are used as samples. Skin fibroblasts can be collected by punch biopsy or the like. The collection site includes the face, the upper arm inner part, the upper arm outer part, the thigh inner part, the thigh outer part, the abdomen, the skin of the back part, etc., and may depend on the method of using the evaluation results, An abdominal part, an upper arm inner part, an inner thigh part, etc., which are non-exposed parts and are not noticeable of wounds at the time of collection, are preferable.
[0010]
The collected skin fibroblasts are embedded in a collagen gel and used for measuring the force generated by the cells. Fibroblast embedding in collagen gel is a known method (Kolodney MS, Wysolmerski RB, Isometric contraction by fibroblasts and endothelial cells in tissue culture: a quantitative study. J Cell Biol., 117, 73-82 (1992), Alternatively, Kolodney MS, Elson EL, Correlation of myosin light chain phosphorylation with isometric contraction of fobroblasts. J Biol Chem, 268, 23850-55 (1993)) can be prepared, for example, as follows.
[0011]
The collected skin fibroblasts are cultured, for example, in Dulbecco's modified Eagle medium (DMEM) containing 5% fetal bovine serum (FBS), and cultured fibroblasts are isolated by a conventional method. FBS-containing DMEM is added to the obtained cells so as to be 3-4 million cells / mL and suspended again. On the other hand, a collagen gel preparation solution is prepared by a conventional method using a collagen solution (Nitta gelatin, type IA). To this collagen gel preparation solution, the previously prepared cell suspension solution is added so that the final cell density becomes 3 × 10 5 cells / mL to 5 × 10 5 cells / mL, and the fibroblast-embedded collagen gel preparation solution is added. Can be produced.
[0012]
On the other hand, a container for producing a collagen gel was produced using silicon rubber, a silicone tube, a cloth tape, a culture dish, and the like. The above fibroblast-embedded collagen gel preparation solution is poured into a groove made of silicon rubber, incubated at 37 ° C. for gelation, and after 24 hours, further incubated in serum-free medium for 1 to 2 days. A blast-embedded collagen gel can be prepared.
[0013]
The collagen used here may be an animal-derived collagen, but in particular, mammals such as humans, mice, rats, rabbits, guinea pigs and cows are preferred. These collagens may be collected and used from tissues by a known method, or commercially available products (for example, type I-A manufactured by Nitta Gelatin Co., Ltd.) may be purchased and used.
[0014]
The force generated in skin fibroblasts embedded in collagen gel is the force generated when actin-myosin polymerizes to form stress fibers, which can be called myofibrils, and contracts. The measurement is performed according to a known method (Kolodney MS, Wysolmerski RB, J Cell Biol., 117, 73-82 (1992), Kolodney MS, Elson EL, J Biol Chem, 268, 23850-23855 (1993)). be able to.
[0015]
For example, one side of the fibroblast-embedded collagen gel prepared above is fixed in a serum-free medium kept at about 37 ° C. in a beaker, and the other is isotonic transducer (for example, Isotonic Transducer, 8 gf, T-7-8-240, ORIENTEC, JAPAN, or PAT-08, Physio Tech.JAPAN, etc.), after applying a load equivalent to 50-300 mg, stabilize for about 30 minutes to 1 hour, Add about 1 mL of stimulating substance prepared in serum-free DMEM medium to a concentration of about 50 times the final concentration, measure the change in force generated with an isotonic transducer, and amplify (for example, Physio Tech., Signal Conditioner MAC -2) After recording (for example, MP100A-CE, AcqKnowledge 3.5, both Biopack system Inc. Santabarbara).
[0016]
The stimulating substance may be any substance that generates a force (tension) by stimulating the actin-myosin system of fibroblasts, such as thrombin, lysophosphatidic acid (LPA), etc. And fetal bovine serum (FBS), monopalmitoyl phosphatidic acid (MLPA), lysophosphatidylcholine palmitoyl (LPCP), endothelin (ET-1), Platelet-derived growth factor (PDGF) can also be used.
[0017]
Using human abdomen-derived dermal fibroblasts (passage number 2-3), subcultured to prepare cells with passage number 5-7 and passage numbers 16-19 (in vitro senescent fibroblasts), When the force generated by the fibroblasts when embedded in collagen gel and stimulated with thrombin and LPA was measured, the senescent fibroblasts showed 4.8 +/− 3.3 dyne and 2.5 +/− 3, respectively. .1 dyne (mean value +/− SD), and significantly reduced cell generation compared to young fibroblasts (32.3 +/− 25.3 dyne, 11.3 +/− 6.8 dyne, respectively) (Example 1). Moreover, when the force which generate | occur | produces the cell at the time of thrombin stimulation was measured about the fibroblast derived from the 62-79-year-old elderly person and the fibroblast derived from 1-4 years old infants, the cell derived from an elderly person is 13.3+. This was /−9.0 dyne, which was significantly lower than cells derived from infants (24.5 +/− 2.0 dyne) (Example 2). That is, the force generated by cells of dermal fibroblasts decreases with age.
Therefore, by measuring the force generated by the skin fibroblasts collected from the subject, the degree of aging of the subject's cells and the degree of aging of the skin can be evaluated.
[0018]
The skin aging evaluation kit of the present invention is a kit for carrying out the above-described method for evaluating the skin aging of a subject, and includes a collagen gel in which the above-described skin fibroblasts are embedded, a stimulating substance, and a cell generation tension measurement. A device (for example, an isotonic transducer or the like) is provided.
[0019]
The evaluation method and evaluation kit of the present invention are used for, for example, a surgical policy in estimating wound healing rate in surgery, a transplant skin creation and selection policy in regenerative medicine, and a guideline for selecting a cosmetic according to skin age. It can be used.
Moreover, the value of the force generated by skin fibroblasts in each age group is prepared as background data, and by comparing this with the data obtained from the subject, the skin age of the subject can be estimated.
[0020]
【Example】
Example 1 Reduction of fibroblast development tension due to in vitro aging (1) Cell human skin fibroblasts (age; 62, sex; male, abdominal origin, passage number 2-3, PDL (Population doubling time) = 6- 8) was purchased from CELL SYSTEMS-Dainippon Pharmaceutical Co., Ltd., and the number of passages at the time of purchase was 3, and the cells were subcultured with 5% FBS-containing DMEM at a split ratio of 1: 4 when confluent. Passage numbers 5-7 were compared as young (Young) and passages 16-19 as old age groups (Old) aged in vitro.
[0021]
(2) Measurement of cell generation force In the collagen gel culture system, the force was measured according to the method of Kolodeny et al. (Kolodney MS, Wysolmerski RB, Isometric contraction by fibroblasts and endothelial cells in tissue culture: a quantitative study. J Cell Biol., 117, 73-82 (1992), Kolodney MS, Elson EL, Correlation of myosin light chain phosphorylation with isometric contraction of fibroblasts. J Biol Chem, 268, 23850-23855 (1993)). Briefly, after fixing and stabilizing fibroblast-embedded collagen gel (1.5 × 10 6 cells, 1.5 mg / mL collagen, Nitta Gelatin Type I-A) in a serum-free medium kept at 37 ° C. Add 1 mL of substance adjusted to a concentration about 50 times the final concentration with serum-free DMEM (final concentration: thrombin = 0.2 U / mL, LPA (lysophosphatidic acid) = 10 μM), and the change in force generated is Measured with Isotonic Transducer (8gf, T-7-8-240, ORIENTEC, JAPAN), amplified (Physio Tech., Signal Conditioner MAC-2) and recorded (MP100A-CE, AcqKnowledge 3.5, both in Biopack system Inc. Santabarbara ).
[0022]
As shown in FIG. 1, it was confirmed that the senescent fibroblasts aged in vitro significantly reduced the power generated by the cells by stimulation with thrombin and LPA as compared with young fibroblasts. Since the number of cells is the same, it is considered that the power generated by individual cells decreased with aging.
[0023]
Example 2 Reduction of fibroblast development tension due to in vivo aging (1) Cells
In vivo senescent cells are DF014 (age; 62, sex; male), DF151 (age; 79, sex; male), DF181 (age; 64, sex; unknown), DF146 (age; 67, sex; male) , DF149 (age; 75, sex; male), 62-79 years old cells (OLD, n = 5), and DF374 (age; 1, sex; male), DF628 (age; 4, sex ; male), DF775 (age; 3, sex; male), (age; 1, sex; male), DF287 (age; 1, sex; female), DF486 (age; 2, sex; male), 1- Cells derived from 4-year-old infants (YNG, n = 5) were used.
[0024]
(2) Measurement of force generated by cells The same method as in Example 1 was used. 1 mL of thrombin solution adjusted to a concentration about 50 times the final concentration with serum-free DMEM (final concentration 0.2 U / mL) was added, and changes in the generated force were observed.
[0025]
As shown in FIG. 2, it was confirmed that the cell-derived force was significantly reduced by thrombin stimulation in the cells derived from the elderly compared with the cells derived from the 4-year-old infant. Since the number of cells is the same, it is considered that the power generated by individual cells decreased with aging.
[0026]
【The invention's effect】
According to the present invention, the skin aging degree of a subject can be evaluated based on the biological aging change of the skin.
[Brief description of the drawings]
BRIEF DESCRIPTION OF DRAWINGS FIG. 1 is a graph showing a decrease in force generation by thrombin and LPA stimulation of in vitro senescent fibroblasts.
FIG. 2 is a diagram showing a decrease in force generation by thrombin stimulation of in vivo senescent fibroblasts.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003150972A JP4235037B2 (en) | 2003-05-28 | 2003-05-28 | Evaluation method of skin aging degree |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003150972A JP4235037B2 (en) | 2003-05-28 | 2003-05-28 | Evaluation method of skin aging degree |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004354159A JP2004354159A (en) | 2004-12-16 |
JP4235037B2 true JP4235037B2 (en) | 2009-03-04 |
Family
ID=34046621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003150972A Expired - Fee Related JP4235037B2 (en) | 2003-05-28 | 2003-05-28 | Evaluation method of skin aging degree |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4235037B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040215066A1 (en) * | 2003-04-23 | 2004-10-28 | Kelly Huang | Method of measuring the efficacy of a skin treatment program |
JP4526971B2 (en) * | 2005-02-14 | 2010-08-18 | 株式会社資生堂 | Evaluation method of skin aging condition using fibulin-5 as an index |
JP5306651B2 (en) | 2005-09-02 | 2013-10-02 | ポーラ化成工業株式会社 | Method for determining skin condition and method for predicting skin thickness |
-
2003
- 2003-05-28 JP JP2003150972A patent/JP4235037B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2004354159A (en) | 2004-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sue et al. | Cochlear origin of hearing loss in MELAS syndrome | |
Ilayperuma | Evaluation of cephalic indices: a clue for racial and sex diversity | |
Rautenstrauch et al. | Progeria: a cell culture study and clinical report of familial incidence | |
Agha‐Hosseini et al. | In vitro isolation of stem cells derived from human dental pulp | |
CA2769174C (en) | Pharmaceutical or cosmetic or dietetic composition for promoting a hair pigmentation effect | |
Olsen et al. | Acoustic reflex and reflex decay: Occurrence in patients with cochlear and eighth nerve lesions | |
Prpić et al. | Association of obesity with periodontitis, tooth loss and oral hygiene in non-smoking adults | |
Do et al. | Accelerated fatigue of dentin with exposure to lactic acid | |
Laosuwan et al. | Comparison of biofilm formation and migration of Streptococcus mutans on tooth roots and titanium miniscrews | |
Ernault et al. | Secretome of atrial epicardial adipose tissue facilitates reentrant arrhythmias by myocardial remodeling | |
TW200540421A (en) | Method for evaluating transparency and moisture-retaining ability of stratum corneum on the basis of oxidized protein in stratum corneum | |
Zhao et al. | The spatial form periosteal-bone complex promotes bone regeneration by coordinating macrophage polarization and osteogenic-angiogenic events | |
JP4235037B2 (en) | Evaluation method of skin aging degree | |
Holm-Pedersen et al. | Strength development of skin incisions in young and old rats | |
Leong et al. | Molecular Assessment of Human Peri-implant Mucosal Healing at Laser-Modified and Machined Titanium Abutments. | |
JP5658696B2 (en) | Evaluation method of skin stress accumulation | |
JP6462437B2 (en) | Evaluation method of skin dryness | |
JP2010500335A (en) | How to treat skin wounds | |
Korraah et al. | Induction of apoptosis and up-regulation of cellular proliferation in oral leukoplakia cell lines inside electric field | |
Hall | Effects of age and sex on static compliance | |
Nair et al. | Age-dependent variation in contractility of adult cardiac myocytes | |
TW201102649A (en) | Metabolites for oral health and uses thereof | |
JP7466721B2 (en) | Improves skin barrier function caused by stress | |
Nadeem | Can fetal ossicles be used as prosthesis in adults? A morphometric study | |
IN2012DN02304A (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051213 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070921 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071023 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080701 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080729 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081209 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081212 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111219 Year of fee payment: 3 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 4235037 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111219 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121219 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121219 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131219 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |